Amgen Lays Out Timeline for KRAS Mutation Studies to Dispel Perceptions of Unethical Rx Development | GenomeWeb

By Turna Ray

This article was posted on Feb. 19.

Although Amgen researchers may have known that the company's colorectal cancer drug Vectibix would eventually have to be marketed with a response biomarker, the drug developer was uncertain about the impact of KRAS mutations on drug response until around the same time it received a negative decision from European regulators for the anti-EGFR monoclonal antibody, an Amgen official recently claimed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.